Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Lynn Quek, Muriel D. David, Alison Kennedy, Marlen Metzner, Michael Amatangelo, Alan Shih, Bilyana Stoilova, Cyril Quivoron, Maël Heiblig, Christophe Willekens, Véronique Saada, Samar Alsafadi, M. S. Vijayabaskar, Andy Peniket, Oliver A. Bernard, Sam Agresta, Katharine Yen, Kyle MacBeth, Eytan Stein, George S. VassiliouRoss Levine, Stephane De Botton, Anjan Thakurta, Virginie Penard-Lacronique, Paresh Vyas

Research output: Contribution to journalArticlepeer-review

134 Scopus citations

Fingerprint

Dive into the research topics of 'Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds